Skip to content
zameds

Lidocaine (Versatis, Remicard, Remicaine, Remicaine Topical, Remicaine Jelly, Xylotox S.E. Plain, Xylotox Plain S.E., Lignotox, Remicane, Locaine)

Lidocaine

Adcock ingram limited

Registration

Applicant
Adcock ingram limited
Certificate holder
Adcock Ingram Ltd
Registrations
13

Variants

ProductStrength and formRegistrationStatusScheduleLeaflets
Versatis 5 %

EACH PLASTER CONTAINS LIDOCAINE 700,0 mg

700 mgMedicated plaster.43038243/3.2.3/0382Approved 2 December 2020RegisteredNot determinedPIPIL
Remicard

EACH 1 ml SOLUTION CONTAINS LIDOCAINE HYDROCHLORIDE 100 mg

Not listedE0035E/6.2/35CancelledNot determinedNone
Remicaine ointment

100 G LIDOCAINE A 5,0 G

OintmentG1347Old MedicineNot determinedNone
Remicaine 4 % topical solution / spray

100 ML LIDOCAINE HYDROCHLORIDE A 4,0 G

4 % /Solution sprayG1348Old MedicineNot determinedNone
Remicaine jelly

EACH 100 g GEL CONTAINS LIDOCAINE HYDROCHLORIDE A 2,0 g

100 gTopical jellyG1349Approved 2 December 2020Old MedicineNot determinedPIPIL
Xylotox S.E. Plain

EACH 2,0 ml SOLUTION CONTAINS :LIDOCAINE HYDROCHLORIDE A 40,0 mg

Not listedG2799Old MedicineNot determinedNone
Xylotox 2 % plain S.E.

EACH 1 ML CONTAINS :LIDOCAINE HYDROCHLORIDE A = ANHYDROUS 20 mg

2 %G2803Old MedicineNot determinedNone
Lignotox

EACh 1 ml SOLUTION CONTAINS LIDOCAINE HYDROCHLORIDE A 20 mg

Not listedG2824Old MedicineNot determinedNone
Remicaine 0,5 %

EACH 20 ML VIAL CONTAINS LIDOCAINE HYDROCHLORIDE A 100 MG

0,5 %G2827Old MedicineNot determinedNone
Remicane 1 % vial

EACH ml SOLUTION CONTAINS LIDOCAINE HYDROCHLORIDE A 10,0 mg

1 %VialG2828Old MedicineNot determinedNone
Remicaine 2 % vial

EACH ML CONTAINS LIDOCAINE HYDROCHLORIDE A 20 MG

2 %VialG2829Old MedicineNot determinedNone
Remicaine 2 % ampoule

EACH 1,0 ml OF SOLUTION CONTIANS LIDOCAINE HYDROCHLORIDE A 20,0 mg

2 %AmpouleG2830Old MedicineNot determinedNone
Locaine

EACH 1 ml SOLUTION CONTAINS LIDOCAINE HYDROCHLORIDE HEMIHYDRATE EQUIVALENT TO 2O mg LIDOCAINE HYDROCHLORIDE

Not listedV0007V/4/7RegisteredNot determinedNone

Regulatory status

This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.

Listings for this ingredient that could not be applied to this product

  • S4: Lidocaine

    • when intended for ophthalmic or parenteral use;
    • when intended for the treatment of neuropathic pain associated with previous herpes zoster infection;
    • except when intended for topical use; (S1)
    • except in oral preparations containing 2 percent or less of lidocaine per dosage form. (S1)

    Consolidated Schedules 06 July 2026, lines 6923 to 6935

  • S1: Lidocaine

    • when intended for topical use;
    • in oral preparations containing 2 percent or less of lidocaine, per dosage unit;
    • except when intended for ophthalmic or parenteral use; (S4)
    • except when intended for the treatment of neuropathic pain associated with previous herpes zoster infection. (S4)

    Consolidated Schedules 06 July 2026, lines 777 to 786

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

C14H22N2O234.34 g/mol

2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide

Drag to rotate. Structure from PubChem CID 3676.

SAHPRA documents

These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.

Background

Loading...
Loading Wikipedia summary

Research articles

Loading...
Loading PubMed articles